ReviewJournal of the American Society of Nephrology : JASN2017
Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells.
Review in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Analysis of the frequency of single nucleotide polymorphisms in cytokine genes in patients with New Onset Diabetes After Transplant.Scientific reports · 2021Trial
- Effects of Desflurane and Sevoflurane anesthesia on regulatory T cells in patients undergoing living donor kidney transplantation: a randomized intervention trial.BMC anesthesiology · 2020Trial
- Relationship between the microenvironment and survival in kidney transplantation: a bibliometric analysis from 2013 to 2023.Frontiers in immunology · 2024Review
- Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview.Journal of clinical medicine · 2022Review
- Regulatory T cells: A review of manufacturing and clinical utility.Transfusion · 2022Review
- Regenerative medicine applications: An overview of clinical trials.Frontiers in bioengineering and biotechnology · 2022Review
- Review
- Lymphocytes: Versatile Participants in Acute Kidney Injury and Progression to Chronic Kidney Disease.Frontiers in physiology · 2021Review
- Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: A case report.Medicine · 2020Article
- Toll-Like Receptor 3 Activator Preconditioning Enhances Modulatory Function of Adipose‑Derived Mesenchymal Stem Cells in a Fully MHC-Mismatched Murine Model of Heterotopic Heart Transplantation.Annals of transplantation · 2020Article
- Medawar's Paradox and Immune Mechanisms of Fetomaternal Tolerance.OBM transplantation · 2020Article
- Review
- Current Clinical Trials in Pemphigus and Pemphigoid.Frontiers in immunology · 2019Review
- Low-dose IL-2 expands CD4Renal failure · 2018Article
- Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2018Review
- HLA in transplantation.Nature reviews. Nephrology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal transplantation is the renal replacement modality of choice for suitable candidates with advanced CKD or ESRD. Prevention of rejection, however, requires treatment with nonspecific pharmacologic immunosuppressants that carry both systemic and nephrologic toxicities. Use of a patient's own suppressive regulatory T cells (Tregs) is an attractive biologic approach to reduce this burden. Here, we review the immunologic underpinnings of Treg therapy and technical challenges to developing successful cell therapy. These issues include the selection of appropriate Treg subsets,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.